Mrsa | Enanta Pharmaceuticals Initiates Phase 1 Study Of MRSA Infection Candidate EDP-788


Enanta Pharmaceuticals, Inc., ( ENTA ) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the initiation of a Phase 1 clinical study of EDP-788, Enanta’s investigational compound for MRSA (methicillin-resistant Staphylococcus aureus ) infections.

EDP-788 is being studied in a randomized double-blind, placebo-controlled clinical study to evaluate the safety and pharmacokinetics of a single oral dose of EDP-788 in up to 64 healthy volunteers.

“With the increased spread of MRSA, as well as other resistant Gram-positive pathogens, there is an urgent need for the development of new antibiotics that will be effective against pathogens that are resistant to current antibiotics,” stated Jay R. Luly, PhD., President and Chief Executive Officer.

Enanta has created a new class of antibiotics called Bicyclolides. EDP-788, Enanta’s lead antibiotic candidate, is a Bicyclolide developed by Enanta that has demonstrated a broad spectrum of activity against many bacterial organisms, including MRSA. This study, as well as all preclinical and early clinical development of EDP-788, is funded under Enanta’s contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

About Bicyclolides and EDP-788

Bicyclolides are a new family of antibiotics created through Enanta’s internal chemistry efforts. They have been designed to overcome resistance and possess a significantly improved product profile compared to existing macrolides. Enanta’s lead Bicyclolide antibiotic product candidate is EDP-788, which is being developed for use as an intravenous drug in the hospital setting and for oral dosing in a home setting. EPD-788 is a pro-drug, which means it is inactive until it is converted in the body into an active compound. Due to its high water solubility, EDP-788 has the benefit of allowing for an intravenous, or IV formulation, as well as oral dosing in pill form.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes ” protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase ” as well as a host-targeted antiviral

Click here to view rest of article from original site

Facebook Twitter Email